Skip to main content
SpringerLink
Log in

Castration-Recurrent Prostate Cancer Is Not Androgen-Independent

  • Chapter
Hormonal Carcinogenesis V

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 617))

In the USA in 2006, an estimated 234,460 new cases of prostate cancer (PC) will be diagnosed and 27,350 men will die from PC (1). Despite the increased use of digital rectal examination and serum prostate-specific antigen (PSA) measurement for early detection, ∼30% of men treated with curative intent suffer PC recurrence. These men and those who present with locally advanced or metastatic PC can be palliated by androgen deprivation therapy (ADT), a treatment that remains unimproved since its discovery more than 60 years ago (2). Over 80% of men with disseminated PC demonstrate clinical or biochemical response that is associated with a mean life expectancy of ∼3.5 years in contrast to nonresponders or untreated patients who live an average of 9 months. Regardless of the androgen responsiveness of incurable PC, almost all patients succumb to castration-recurrent PC because it responds poorly to all known therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Siegel R, Ward E, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106–130.

    Article  PubMed  Google Scholar 

  2. Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168: 9–12.

    Article  PubMed  Google Scholar 

  3. Mohler JL, Gregory CW, Ford OH III, et al. (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440–448.

    Article  PubMed  CAS  Google Scholar 

  4. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al. (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189–193.

    Article  PubMed  Google Scholar 

  5. Visakorpi T, Hyytinen E, Koivisto P, et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401–406.

    Article  PubMed  CAS  Google Scholar 

  6. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45.

    Article  PubMed  CAS  Google Scholar 

  7. Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20: 3001–3015.

    Article  PubMed  CAS  Google Scholar 

  8. Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687–1697.

    Article  PubMed  CAS  Google Scholar 

  9. Sadar MD, Hussain M, Bruchovsky N (1999) Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6: 487–502.

    Article  PubMed  CAS  Google Scholar 

  10. Takahashi H, Furusato M, Allsbrook WC, Jr, et al. (1995) Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 55: 1621–1624.

    PubMed  CAS  Google Scholar 

  11. Tilley WD, Buchanan G, Hickey TE, et al. (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2: 277–285.

    PubMed  CAS  Google Scholar 

  12. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, et al. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144: 735–746.

    PubMed  CAS  Google Scholar 

  13. Taplin ME, Bubley GJ, Shuster TD, et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393–1398.

    Article  PubMed  CAS  Google Scholar 

  14. Greene SL, Stockton P, Kozyreva OG, et al. (2003) Mutational analysis of the androgen receptor using laser capture microdissection and direct sequencing. In: Terrain D (ed.) Cancer Cell Signalling: Methods and Protocols. Humana Press, Totowa, NJ, pp. 287–302.

    Google Scholar 

  15. Taplin ME, Bubley GJ, Ko YJ, et al. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511–2515.

    PubMed  CAS  Google Scholar 

  16. Shi XB, Ma AH, Xia L, et al. (2002) Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 62: 1496–1502.

    PubMed  CAS  Google Scholar 

  17. Culig Z, Hobisch A, Cronauer MV, et al. (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541–1550.

    Article  PubMed  CAS  Google Scholar 

  18. Peterziel H, Culig Z, Stober J, et al. (1995) Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 63: 544–550.

    Article  PubMed  CAS  Google Scholar 

  19. Tan J, Sharief Y, Hamil KG, et al. (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11: 450–459.

    Article  PubMed  CAS  Google Scholar 

  20. Chen CD, Welsbie DS, Tran C, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33–39.

    Article  PubMed  Google Scholar 

  21. Ford OH, 3rd, Gregory CW, Kim D, et al. (2003) Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170: 1817–1821.

    Article  PubMed  CAS  Google Scholar 

  22. Palmberg C, Koivisto P, Kakkola L, et al. (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164: 1992–1995.

    Article  PubMed  CAS  Google Scholar 

  23. Ueda T, Bruchovsky N, Sadar MD (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277: 7076–7085.

    Article  PubMed  CAS  Google Scholar 

  24. Ueda T, Mawji NR, Bruchovsky N, et al. (2002) Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277: 38087–38094.

    Article  PubMed  CAS  Google Scholar 

  25. Yeh S, Lin HK, Kang HY, et al. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96: 5458–5463.

    Article  PubMed  CAS  Google Scholar 

  26. Liu Y, Majumder S, McCall W, et al. (2005) Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65: 3404–3409.

    PubMed  CAS  Google Scholar 

  27. Mahajan NP, Whang YE, Mohler JL, et al. (2005) Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 65: 10514–10523.

    Article  PubMed  CAS  Google Scholar 

  28. Park SY, Kim YJ, Gao AC, et al. (2006) Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 66: 5121–5129.

    Article  PubMed  CAS  Google Scholar 

  29. Smitherman AB, Gregory CW, Mohler JL (2003) Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft. Prostate 57: 24–31.

    Article  PubMed  CAS  Google Scholar 

  30. Dai J, Shen R, Sumitomo M, et al. (2002) Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 8: 2399–2405.

    PubMed  CAS  Google Scholar 

  31. Titus MA, Schell MJ, Lih FB, et al. (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653–4657.

    Article  PubMed  CAS  Google Scholar 

  32. Belanger B, Belanger A, Labrie F, et al. (1989) Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 32: 695–698.

    Article  PubMed  CAS  Google Scholar 

  33. Labrie F, Dupont A, Belanger A, et al. (1982) New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5: 267–275.

    PubMed  CAS  Google Scholar 

  34. Prostate Cancer Trialists’ Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 265–269.

    Google Scholar 

  35. Eisenberger MA, Blumenstein BA, Crawford ED, et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036–1042.

    Article  PubMed  CAS  Google Scholar 

  36. Geller J, Albert J, Loza D (1979) Steroid levels in cancer of the prostate –markers of tumour differentiation and adequacy of anti-androgen therapy. J Steroid Biochem 11: 631–636.

    Article  PubMed  CAS  Google Scholar 

  37. Mizokami A, Koh E, Fujita H, et al. (2004) The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64: 765–771.

    Article  PubMed  CAS  Google Scholar 

  38. Nishiyama T, Hashimoto Y, Takahashi K (2004) The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10: 7121–7126.

    Article  PubMed  CAS  Google Scholar 

  39. Page ST, Lin DW, Mostaghel EA, et al. (2006) Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men. J Clin Endocrinol Metab 91: 3850–3856.

    Article  PubMed  CAS  Google Scholar 

  40. Simard J, Luthy I, Guay J, et al. (1986) Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261–270.

    Article  PubMed  CAS  Google Scholar 

  41. Gregory CW, Johnson RT, Jr, Mohler JL, et al. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892–2898.

    PubMed  CAS  Google Scholar 

  42. Culig Z, Hoffmann J, Erdel M, et al. (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81: 242–251.

    Article  PubMed  CAS  Google Scholar 

  43. Stege R, Tribukait B, Lundh B, et al. (1992) Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 148: 833–837.

    PubMed  CAS  Google Scholar 

  44. Yang Y, Chisholm GD, Habib FK (1992) The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate. Prostate 21: 201–208.

    Article  PubMed  CAS  Google Scholar 

  45. Bartsch W, Klein H, Schiemann U, et al. (1990) Enzymes of androgen formation and degradation in the human prostate. Ann N Y Acad Sci 595: 53–66.

    Article  PubMed  CAS  Google Scholar 

  46. Gregory CW, He B, Johnson RT, et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315–4319.

    PubMed  CAS  Google Scholar 

  47. Harper ME, Pike A, Peeling WB, et al. (1974) Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 60: 117–125.

    Article  PubMed  CAS  Google Scholar 

  48. Kim D, Gregory CW, French FS, et al. (2002) Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol 160: 219–226.

    PubMed  CAS  Google Scholar 

  49. Taplin ME, Balk SP (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483–490.

    Article  PubMed  CAS  Google Scholar 

  50. Edwards J, Krishna NS, Grigor KM, et al. (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89: 552–556.

    Article  PubMed  CAS  Google Scholar 

  51. Linja MJ, Savinainen KJ, Saramaki OR, et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550–3555.

    PubMed  CAS  Google Scholar 

  52. Brown RS, Edwards J, Dogan A, et al. (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198: 237–244.

    Article  PubMed  CAS  Google Scholar 

  53. Hobisch A, Culig Z, Radmayr C, et al. (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55: 3068–3072.

    PubMed  CAS  Google Scholar 

  54. Hsing AW, Reichardt JK, Stanczyk FZ (2002) Hormones and prostate cancer: current perspectives and future directions. Prostate 52: 213–235.

    Article  PubMed  CAS  Google Scholar 

  55. Stanbrough M, Bubley GJ, Ross K, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815–2825.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologic Oncology University of North Carolina, Chapel Hill, NC, USA

    James L. Mohler

Authors
  1. James L. Mohler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Center Department of Pharmacology, University of Kansas, Kansas City, KS, USA

    Jonathan J. Li PhD  & Sara A. Li PhD  & 

  2. Division of Cancer Biology, National Cancer Institute, Rockville, MD, USA

    Suresh Mohla PhD

  3. Hormone and Cancer Unit, U540, Montpellier University and INSERM, Montpellier, France

    Henri Rochefort MD/PhD

  4. Department of Cell Biology, Montpellier University 1-INSERM, U540 Hospital Arnaud de Villeneuve, Montpellier, France

    Thierry Maudelonde MD/PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Mohler, J.L. (2008). Castration-Recurrent Prostate Cancer Is Not Androgen-Independent. In: Li, J.J., Li, S.A., Mohla, S., Rochefort, H., Maudelonde, T. (eds) Hormonal Carcinogenesis V. Advances in Experimental Medicine and Biology, vol 617. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69080-3_21

Download citation

Publish with us

Policies and ethics

Search

Navigation